Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SANA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSana Biotechnology reports Q1 2026 financial results
Filed May 11, 2026 · Period ending May 11, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for the quarter ended March 31, 2026. Actual figures are in the attached press release, not in the 8-K body itself.
Item 2.02 verify on EDGAR → -
low
This is a routine quarterly earnings announcement filing. The 8-K references the press release as Exhibit 99.1 but does not contain detailed financial data.
8-K: Earnings view on EDGAR →
Summary
Sana Biotechnology filed an 8-K to announce its first quarter 2026 financial results via press release on May 11, 2026. This is a standard quarterly earnings disclosure required by SEC rules. The filing itself does not contain the actual financial figures—those details are in the attached press release (Exhibit 99.1), which was not included in the analysis.
For retail investors, this is a routine procedural filing. The key information to review is the press release itself, which should contain revenue, expenses, cash position, and any updates on clinical programs or business developments. Watch for management commentary on cash runway and progress in Sana's cell therapy pipeline, as these are critical metrics for a pre-revenue biotech company.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Sana Biotechnology announced Q1 2026 financial results via press release on May 11, 2026.
Added in current filing · verify on EDGAR →
On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release as Exhibit 99.1. This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Sana Biotechnology filed an 8-K attaching a press release dated May 11, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press release of Sana Biotechnology, Inc. dated May 11, 2026
The 8-K lists a press release dated May 11, 2026 as Exhibit 99.1. The filing body provides no details about the content of the press release, so the nature and materiality of any disclosed event cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify